SARS‐CoV‐2 acute bronchiolitis in hospitalized children: Neither frequent nor more severe
Authors:
- David Andina‐MartinezDADavid Andina‐Martinez
- Jose Antonio Alonso-CadenasJAJose Antonio Alonso-Cadenas
- Cristina EpalzaCECristina Epalza
- Cinta MoraledaCMCinta Moraleda
- Alfredo TagarroATAlfredo Tagarro
- the EPICO‐AEP Working GroupTGthe EPICO‐AEP Working Group
Open Access
- 25 October 2021
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 57 (1) , 57-65
Abstract
Introduction: Endemic coronaviruses have been found in acute bronchiolitis, mainly as a coinfecting virus. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been responsible for respiratory illness in hospitalized children. The characteristics of patients with bronchiolitis have not been extensively described.Methods: Cross‐sectional study of patients with bronchiolitis and SARS‐CoV‐2 infection enrolled in a prospective multicenter cohort of children hospitalized with COVID‐19 in Spain from March 1, 2020 to February 28, 2021.Results: Twelve of 666 children infected with SARS‐CoV‐2 who required hospital admission met the diagnostic criteria for bronchiolitis (1.8%). Median age was 1.9 months (range: 0.4–10.1). Six cases had household contact with a confirmed or probable COVID‐19 case. Main complaints were cough (11 patients), rhinorrhea (10), difficulty breathing (8), and fever (8). Eleven cases were classified as mild or moderate and one as severe. Laboratory tests performed in seven patients did not evidence anemia, lymphopenia, or high C‐reactive protein levels. Chest X‐rays were performed in six children, and one case showed remarkable findings. Coinfection with metapneumovirus was detected in the patient with the most severe course; Bordetella pertussis was detected in another patient. Seven patients required oxygen therapy. Albuterol was administered in four patients. One patient was admitted to the pediatric intensive care unit. Median length of admission was 4 days (range: 3–14). No patient died or showed any sequelae at discharge. Two patients developed recurrent bronchospasms.Conclusion: SARS‐CoV‐2 infection does not seem to be a main trigger of severe bronchiolitis, and children with this condition should be managed according to clinical practice guidelines.Keywords
This publication has 31 references indexed in Scilit:
- Clinical Practice Guideline: The Diagnosis, Management, and Prevention of BronchiolitisPediatrics, 2014
- Overuse of bronchodilators and steroids in bronchiolitis of different severityAllergologia et Immunopathologia, 2014
- Bronchiolitis Management Before and After the AAP GuidelinesPediatrics, 2014
- Viral Etiologies of Infant Bronchiolitis, Croup and Upper Respiratory Illness During 4 Consecutive YearsThe Pediatric Infectious Disease Journal, 2013
- Trends in Bronchiolitis Hospitalizations in the United States, 2000–2009Pediatrics, 2013
- Etiología de bronquiolitis en niños hospitalizados en el sureste de EspañaAnales de Pediatría, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Impact of human metapneumovirus and respiratory syncytial virus co‐infection in severe bronchiolitisPediatric Pulmonology, 2007
- Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000The Journal of Pediatrics, 2003
- BronchiolitisAmerican Journal of Diseases of Children, 1983